DANAHER

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Retrieved on: 
Thursday, May 9, 2024
Johns Hopkins University, Traumatic brain injury, MSN, Danaher Corporation, BSN, Risk, DHR, Blood, Johns Hopkins, MD, Doctor of Philosophy, Research, TBI, Brain damage, Beacon, Patient, RN, Diagnosis, Brain, Biomarker, Emergency medicine, Medical imaging

This approach could potentially be adapted for diagnosis of other neurological conditions.

Key Points: 
  • This approach could potentially be adapted for diagnosis of other neurological conditions.
  • WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.
  • As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
  • The Danaher Beacon for Brain Injury Diagnostics is the sixth collaboration in the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

Sonova announces Management Board succession

Retrieved on: 
Friday, May 10, 2024
Immersion, Consumer, Lilika, Bionics, LivaNova, Johnson & Johnson, GVP, Knowledge

Stäfa (Switzerland), May 7, 2024 – Sonova Holding AG, a leading provider of hearing care solutions, today announces upcoming appointments to its Management Board.

Key Points: 
  • Stäfa (Switzerland), May 7, 2024 – Sonova Holding AG, a leading provider of hearing care solutions, today announces upcoming appointments to its Management Board.
  • They have built strong teams and created good foundations for their successors and Sonova.
  • They have also demonstrated their leadership capabilities in various senior positions across different regions and businesses at Sonova.
  • Arnd comments: “We are excited that these three experienced leaders join our Management Board.

Lazard Welcomes Michele Colocci as Vice Chairman, Investment Banking and Managing Director, Healthcare

Retrieved on: 
Thursday, May 9, 2024
Finance, Consulting, Banking, Professional Services, Asset Management, Sale, JPMorgan Chase, Element, Investment banking, Reata Pharmaceuticals, AbbVie, Morgan Stanley, Vice, Bain & Company, CVS Health, Harvard Business School, Bain, Williams College, IPO, Acquisition, Peter R. Orszag, Oak Street Health, LAZ, Growth, Pharmaceutical industry

Lazard, Inc. (NYSE: LAZ) today announced Michele Colocci is joining the firm on 3rd June 2024 as Vice Chairman, Investment Banking and Managing Director, Healthcare.

Key Points: 
  • Lazard, Inc. (NYSE: LAZ) today announced Michele Colocci is joining the firm on 3rd June 2024 as Vice Chairman, Investment Banking and Managing Director, Healthcare.
  • Mr. Colocci is a globally recognized advisor with a particular focus on healthcare, having worked with biopharma clients across EMEA, the US, and Japan.
  • With three decades of investment banking expertise, he most recently served as Managing Director and Chairman of M&A at Morgan Stanley, where among other previous leadership roles, he also served as Global Co-Head of Healthcare Investment Banking and as Deputy Head of European Investment Banking.
  • He previously also held the role of Global Co-Head of Healthcare Investment Banking at JPMorgan.

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Monday, April 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

Global Research Antibodies & Reagents Market Outlook & Forecasts, 2023 and 2024-2029: Growing Demand for Precision Medicine, Rising Focus on Biomarker Discovery, & Rise in Proteomics and Genomics - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, USD, Immunoprecipitation, Antibody, Cancer, Genomics, Protein, Cell biology, ELISA, Heart, Personalized medicine, Proteomics, Immunohistochemistry, Biomedical Research, Biomarker, Growth, University, Disease, ChromeOS, Bio-Rad Laboratories, Therapy, Northern blot, Patient, Chemistry, Medicine, Diagnosis, Antigen, Gene expression, Genome, Elisa's, Drug development, Biology, Molecular biology, Drug discovery, Thermo Fisher Scientific, Gene, Flow cytometry, Fine chemical

North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.

Key Points: 
  • North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.
  • This paradigm shift presents a substantial opportunity for the research antibodies & reagents market, an essential component of precision medicine research.
  • The reagents product type accounted for the most significant global research antibodies & reagents market share in 2023.
  • The academics & research institutes and research labs end-user segment dominated the global research antibodies & reagents market share in 2023.

Danaher Reports First Quarter 2024 Results

Retrieved on: 
Tuesday, April 23, 2024
Cepheid variable, Webcast, Danaher Corporation, GAAP, Conference, DHR, Bank

WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024.
  • For the second quarter 2024, the Company anticipates that non-GAAP core revenue will be down mid-single digits year-over-year.
  • Danaher will discuss its first quarter results and financial guidance for the second quarter and full year 2024 during its quarterly investor conference call today starting at 8:00 a.m.
  • A replay of the conference call will be available shortly after the conclusion of the call and until May 7, 2024.

Does Compostable Packaging Actually Break Down? Composting Consortium Reveals Groundbreaking Findings from Largest Field Test in North America

Retrieved on: 
Tuesday, April 16, 2024
Education, Methane, University College London, PepsiCo, Agitation, Atlas, Compost, Growth, Colgate-Palmolive, Food, UCL, CMA, Overalls, ASTM International, RRS, Kraft Heinz, Sustainability, PLA, Circular economy, BPI, WWF, Research, SPC, CREF, Target Corporation, Western Michigan University, WMU, Recycling, CFTP, University, FPI, Consortium, Environment, Oxygen, Foodservice

NEW YORK, April 16, 2024 /PRNewswire/ -- Today, the Composting Consortium, an industry collaboration led by the Center for the Circular Economy at Closed Loop Partners, released a groundbreaking report that fills a critical data gap for the U.S. composting industry: how well does certified, food-contact compostable packaging actually break down in real-world composting facilities? The report, Breaking It Down: The Realities of Compostable Packaging Disintegration in Composting Systems, shares findings from an 18-month study––the largest known field test of certified, food-contact compostable packaging conducted in North America––revealing the realities of compostable plastic and fiber disintegration in diverse in-field composting conditions.

Key Points: 
  • The report, Breaking It Down: The Realities of Compostable Packaging Disintegration in Composting Systems , shares findings from an 18-month study––the largest known field test of certified, food-contact compostable packaging conducted in North America––revealing the realities of compostable plastic and fiber disintegration in diverse in-field composting conditions.
  • In total, the study tested over 23,000 units of certified food-contact compostable packaging within large-scale industrial composting environments.
  • This encompassed 31 types of fiber packaging & products and compostable plastic packaging & products––such as PLA and PHA––across 10 diverse composting facilities across the U.S.
  • The findings point to the viability of certified food-contact compostable packaging as an alternative packaging solution to single-use conventional plastic packaging.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Danaher Schedules First Quarter 2024 Earnings Conference Call

Retrieved on: 
Thursday, March 21, 2024
Webcast, Danaher Corporation, Conference, DHR

WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m.

Key Points: 
  • WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m.
  • ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ124).
  • A replay of the conference call will be available shortly after the conclusion of the call until May 7, 2024.
  • Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m.

Abcam appoints Markus Lusser as new President

Retrieved on: 
Monday, March 18, 2024
LMS, HTBLA, Culture, Growth, Leica Microsystems, Siemens Healthineers, Heart, Management

CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.

Key Points: 
  • CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.
  • A seasoned Danaher executive, Markus joins Abcam at a pivotal moment as the company transitions into the Danaher Life Sciences portfolio.
  • Prior to joining Danaher, Markus was responsible for large global commercial organizations, including 20 years at Siemens Healthineers.
  • As an experienced people leader, Markus is passionate about building and developing the skills and experience of his cross-functional teams.